For research use only. Not for therapeutic Use.
Riociguat-13C,d6, a premium pharmaceutical research compound designed for advanced cardiovascular and pulmonary studies. As an isotopically labeled analog of Riociguat, it offers enhanced stability and precise isotopic tracking. Riociguat-13C,d6 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for pulmonary hypertension and other cardiovascular conditions. Trusted by leading laboratories, Riociguat-13C,d6 is your go-to solution for cutting-edge cardiovascular and pulmonary research. Unlock new possibilities in heart and lung disease treatment with Riociguat-13C,d6, where innovation meets reliability.
| Catalog Number | S000244 |
| Molecular Formula | C1913CH13D6FN8O2 |
| Purity | ≥95% |
| SMILES | O=C(OC([2H])([2H])[2H])N(C1=C(N)N=C(C2=NN(CC3=CC=CC=C3F)C4=NC=CC=C42)N=C1N)[13C]([2H])([2H])[2H] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-223. [2]. Schermuly RT, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008 Oct;32(4):881-91. [3]. Schermuly RT, et al. Riociguat for the treatment of pulmonary hypertension.Expert Opin Investig Drugs. 2011 Apr;20(4):567-76. |
